Despite the fact that coronary artery bypass grafting surgery (CABG) with cardiopulmonary bypass (CPB) prolongs life and\nreduces symptoms in patients with severe coronary artery diseases, these benefits are accompanied by increased risks. Morbidity\nassociatedwith cardiopulmonary bypass can be attributed to the generalized inflammatory response induced by blood-xenosurfaces\ninteractions during extracorporeal circulation and the ischemia/reperfusion implications, including exacerbated inflammatory\nresponse resembling the systemic inflammatory response syndrome (SIRS). The use of specific anesthetic agents with antiinflammatory\nactivity can modulate the deleterious inflammatory response. Consequently, anti-inflammatory anesthetics may\naccelerate postoperative recovery and better outcomes than classical anesthetics. It is known that the stress response to surgery\ncan be attenuated by sympatholytic effects caused by activation of central (????-)2-adrenergic receptor, leading to reductions in blood\npressure and heart rate, and more recently, that they can have anti-inflammatory properties. This paper discusses the clinical\nsignificance of the dexmedetomidine use, a selective (????-)2-adrenergic agonist, as a coadjuvant in general anesthesia. Actually,\ndexmedetomidine use is not in anesthetic routine, but this drug can be considered a particularly promising agent in perioperative\nmultiple organ protection.
Loading....